Consun Pharmaceutical Group Limited
Consun Pharmaceutical Group Limited Fundamental Analysis
Consun Pharmaceutical Group Limited (1681.HK) shows strong financial fundamentals with a PE ratio of 11.86, profit margin of 31.55%, and ROE of 24.04%. The company generates $3.4B in annual revenue with strong year-over-year growth of 14.56%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 81.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 1681.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent1681.HK demonstrates superior asset utilization.
Valuation Score
Moderate1681.HK shows balanced valuation metrics.
Growth Score
Excellent1681.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent1681.HK maintains a strong and stable balance sheet.
Profitability Score
Excellent1681.HK achieves industry-leading margins.
Key Financial Metrics
Is 1681.HK Expensive or Cheap?
P/E Ratio
1681.HK trades at 11.86 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 1681.HK's PEG of 2.70 indicates potential overvaluation.
Price to Book
The market values Consun Pharmaceutical Group Limited at 2.79 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 11.37 times EBITDA. This signals the market has high growth expectations.
How Well Does 1681.HK Make Money?
Net Profit Margin
For every $100 in sales, Consun Pharmaceutical Group Limited keeps $31.55 as profit after all expenses.
Operating Margin
Core operations generate 34.33 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $24.04 in profit for every $100 of shareholder equity.
ROA
Consun Pharmaceutical Group Limited generates $16.66 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Consun Pharmaceutical Group Limited generates strong operating cash flow of $1.22B, reflecting robust business health.
Free Cash Flow
Consun Pharmaceutical Group Limited generates strong free cash flow of $1.14B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.35 in free cash annually.
FCF Yield
1681.HK converts 9.07% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.86
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.70
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.79
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.72
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.22
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.24
vs 25 benchmark
ROA
Return on assets percentage
0.17
vs 25 benchmark
ROCE
Return on capital employed
0.23
vs 25 benchmark
How 1681.HK Stacks Against Its Sector Peers
| Metric | 1681.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.86 | 28.45 | Better (Cheaper) |
| ROE | 24.04% | 763.00% | Weak |
| Net Margin | 31.55% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.05 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 3.22 | 2795.60 | Strong Liquidity |
| ROA | 16.66% | -16588.00% (disorted) | Strong |
1681.HK outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Consun Pharmaceutical Group Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
77.48%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
1079.08%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
193.13%
Industry Style: Defensive, Growth, Innovation
High Growth